Next Article in Journal
Botulinum Toxin—A High-Dosage Effect on Functional Outcome and Spasticity-Related Pain in Subjects with Stroke
Previous Article in Journal
Expression of Cholera Toxin (CT) and the Toxin Co-Regulated Pilus (TCP) by Variants of ToxT in Vibrio cholerae Strains
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

A Multi-Layer-Controlled Strategy for Cloning and Expression of Toxin Genes in Escherichia coli

Center for Structural Biology, Vlaams Instituut voor Biotechnologie and Structural Biology Brussels, Vrije Universiteit Brussel, Pleinlaan 2, B-1050 Brussel, Belgium
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Toxins 2023, 15(8), 508; https://doi.org/10.3390/toxins15080508
Submission received: 5 April 2023 / Revised: 17 July 2023 / Accepted: 8 August 2023 / Published: 18 August 2023
(This article belongs to the Section Bacterial Toxins)

Abstract

:
Molecular cloning and controlled expression remain challenging when the target gene encodes a protein that is toxic to the host. We developed a set of multi-layer control systems to enable cloning of genes encoding proteins known to be highly toxic in Escherichia coli and other bacteria. The different multi-layer control systems combine a promoter–operator system on a transcriptional level with a riboswitch for translational control. Additionally, replicational control is ensured by using a strain that reduces the plasmid copy number. The use of weaker promoters (such as PBAD or PfdeA) in combination with the effective theophylline riboswitch is essential for cloning genes that encode notoriously toxic proteins that directly target translation and transcription. Controlled overexpression is possible, allowing the system to be used for evaluating in vivo effects of the toxin. Systems with a stronger promoter can be used for successful overexpression and purification of the desired protein but are limited to toxins that are more moderate and do not interfere with their own production.
Key Contribution: This study provides an efficient system to clone (and express) genes encoding highly toxic proteins in bacteria by reducing leaky expression to the minimum.

1. Introduction

Cloning and production of recombinant proteins are well-established techniques in molecular biology. They are routinely carried out in a variety of both prokaryotic and eukaryotic hosts. Escherichia coli (E. coli) is often the preferred host organism because of its short generation time of 20 min, high ability of exogeneous DNA uptake and efficient protein expression [1,2,3]. Still, cloning of genes encoding proteins that interfere with bacterial growth or otherwise exhibit toxic effects often remains challenging.
One way to circumvent toxic effects is by using bacterial strains that are resistant to a particular toxin. This has for example been proven successful for toxins CcdB and VapC, where efficient cloning and production of the wild-type toxins was possible [4,5]. Unfortunately, such resistant strains are more than often not available. In particular, endoribonucleases pose problems as it is unfeasible to mutate their RNA targets. Moreover, the development of a suitable resistant strain can be time-consuming as it requires prior insight into the toxin–target relationship.
A different way to manage cloning of weakly toxic genes is to lower the copy number of their harboring plasmid. Regulation of plasmid replication can be accomplished by using low copy-number vectors that tightly regulate the toxin’s expression, a well-known example being the pBAD vectors [6]. Alternatively, one can consider the use of low copy number strains such as the CopycutterTM EPI400TM E. coli strain, which is optimized for cloning toxic genes. Such strains reduce the copy number of pUC- or pET-vectors to only 10 copies per cell, but upon induction, the copy number will increase significantly, resulting in higher yields of toxin protein [7].
However, even with low plasmid copy numbers, leaky expression might still pose problems and needs to be suppressed. This can be achieved on both the transcriptional and/or translational levels. Most gene expression control systems are solely based on transcriptional regulation. The use of an inducible promoter regulates transcription of the downstream gene(s) stringently in time and space. Common examples of chemically inducible promoters are the strong IPTG-inducible Plac or its stronger derivative Ptac and the weaker arabinose-inducible PBAD, where expression can be repressed by glucose, reducing leaky transcription [6,8,9]. In practice, however, such systems are not tight ON/OFF switches and leaky expression is almost inevitable. Besides chemical inducers, temperature-inducible promoters known for limited leakiness also exist. However, there is often a stress burden linked to the shifts in temperature [10]. The promoter region can also be mutated as such to reduce its activity and thus leaky expression as described by [11]. There, a two-thymidine deletion in the −35 region of the T5 promoter led to the successful cloning of the ϕ174 lysis gene E. As a last resort, site-specific point mutations in the toxin gene that render the toxin harmless for the cell can be introduced to enable the cloning and overexpression of the non-toxic protein. Examples of such non-toxic mutants are E. coli MazFE24A (EcMazFE24A) or bacteriophage P1 DocH66Y (P1DocH66Y) [12,13]. Nonetheless, mutating the toxin often results in loss of functionality, limiting the usefulness of downstream experiments severely.
In addition to transcriptional control, regulation at the translational level is described in literature. These include ribozymes that are activated by bound ligands enabling site-specific digestion of RNA to control gene expression, antisense RNAs or the incorporation of site-specific unnatural amino acids [14,15,16,17]. Another well-known translational control element is the riboswitch. This is an RNA element that functions by regulating protein expression in response to the presence of a certain metabolite. Riboswitches consist of two domains, called the aptamer and the expression platform. The aptamer domain selectively binds a metabolite, thereby causing the formation of a terminator structure in the expression platform. This conformational change in RNA structure controls the expression of the downstream gene [18]. Different riboswitches have been discovered, engineered or synthesized in the past. Examples are the adenine riboswitch, vitamin B12 riboswitch, theophylline riboswitch and many more [19,20,21].
Altogether, for all the strategies described above, several disadvantages remain. Controlling expression on either the transcriptional or the translational level often seems insufficient to avoid leaky expression of highly toxic genes. Therefore, a combination of both is frequently desired. Combined transcription–translation regulating systems have already been developed and reported in the past (for a review, see [22]). A dual-control system named RiboTite, using inducible promoters and a riboswitch, was reported by Morra et al. [23]. Other authors make use of antisense RNA (asRNA) regulators that are configured in such a way that it targets both transcriptional and translational regulation to increase the control over gene expression [15]. Lee et al. furthermore discussed the combined use of asRNA and small transcription-activating RNA for deactivation or activation of gene expression, respectively [24]. The use of asRNA has also been combined with the use of a strong repressible promoter [25]. Additionally, dual control over gene expression has been achieved by constructing tandem theophylline riboswitches and the RepA protein degradation tag, targeting both transcription and post-translational regulation [26].
Among the most difficult toxic genes to clone are those encoded by bacterial toxin–antitoxin (TA) systems. The toxins on their own can almost never be cloned without introducing mutations; even cloning the operon, including both toxin and antitoxin genes, can sometimes be cumbersome, e.g., for the phd/doc homolog tasAB [27]. Here, we describe and evaluate a novel multi-control system where TA toxins are cloned and expressed in the absence of their cognate antitoxin. This model system inhibits leaky expression on various levels: (1) on the replicational level using a strain that reduces the plasmid copy number, (2) on the transcriptional level by a tightly controllable inducible promoter and (3) on the translational level using a ligand-dependent riboswitch.

2. Results and Discussion

2.1. Choice of Toxins

The initial motivation for developing this cloning strategy was our search to clone the extremely potent parE2 toxin gene from Vibrio cholerae. To demonstrate the broader applicability of our multi-control system, we selected a set of seven toxins with distinct activities and levels of toxicity to evaluate its usefulness for cloning toxins. Six out of the seven toxins are part of a toxin–antitoxin system: Escherichia coli MazF (EcMazF), Vibrio cholerae HigB2 (VcHigB2) bacteriophage P1 Doc (P1Doc), E. coli O157 and V. cholerae ParE2 (EcParE2 and VcParE2) and F-plasmid CcdB (FCcdB). These toxins represent three different activities: ribonuclease (RNase), translation-inhibiting kinase and gyrase poisoning activity. MazF toxins are endoribonucleases (RNases) that cut mRNA at 5′ ACA sites, while HigB2 toxins are ribosome-dependent RNases that cut mRNA, which is actively being translated [28,29]. Doc inhibits translation by phosphorylating elongation factor Tu, and CcdB and ParE2 toxins interfere with transcription and replication by poisoning gyrase [30,31,32,33]. In addition, two non-toxic point mutants were added as controls: H66Y for P1Doc and E24A for EcMazF. These point mutants can be overexpressed in the absence of their cognate antitoxin and produced with high yields [12,13]. Finally, barnase was included in our screen. This scavenging ribonuclease from Bacillus amyloliquefaciens is exported but gets protected via its interaction with its inhibitor barstar while inside the cell [34].

2.2. Design of Different Multi-Control Systems

Two different riboswitches were evaluated for their ability to control translation tightly: a vitamin B12 riboswitch and a synthetic theophylline riboswitch. The vitamin B12 riboswitch originates from the btuB gene encoding the BtuB receptor protein located in the outer membrane of E. coli [20]. When vitamin B12 is present, it binds to the aptamer domain of the riboswitch (Figure 1A,B). This results in a conformation where the ribosome binding site (RBS) on the transcript is shielded, causing translational repression (OFF-state). Once vitamin B12 is removed, translation is initiated and ribosomal access to the RBS is restored (ON-state). The synthetic theophylline riboswitch was initially created for tightly regulated expression of chloroplast genes [21]. It works in the opposite way compared to vitamin B12: the presence of theophylline ensures translation of the downstream gene(s) as the RBS is accessible (Figure 1C,D).
To add a transcriptional layer of control, the riboswitches described above were combined with different promoter–operator systems. In the first system (Figure 1A), the vitamin B12 riboswitch was combined with the naringenin-inducible promoter PfdeA to regulate gene expression on a transcriptional level [35]. In the presence of naringenin, the transcriptional activator FdeR binds to the operator site fdeO, thereby initiating transcription.
As the PfdeA promoter is rather weak for overexpression of the toxin, a second system was designed where PfdeA was exchanged for the stronger IPTG-inducible tac promoter (Ptac) (Figure 1B). This hybrid promoter combines the −35 region of the trp promoter with the −10 region of the lacUV5 promoter–operator region [9]. As Ptac is a strong promoter, it is mainly of interest when aiming for protein production. Similar to PfdeA, Ptac is a negatively inducible promoter that is controlled by the inactivation of the LacI repressor via allolactose or its analog isopropyl β-D-1-thiogalactopyranoside (IPTG). The presence of the latter compounds changes the conformation of the LacI repressor, which restrains its binding to the lacO operator and consequently allows transcription. In order to compare the efficiency of both the B12 and theophylline riboswitches, a similar system combining Ptac with the theophylline riboswitch was designed (Figure 1C).
Finally, the tightly regulated arabinose-inducible promoter (PBAD) was included in this study in combination with the theophylline riboswitch (Figure 1D). PBAD is regulated by the activator AraC. In the absence of arabinose, AraC binds to the O and I1 sites, thereby preventing transcription. Only when arabinose is bound to AraC, transcription is initiated as AraC binds to the I1 and I2 sites.
As an extra layer of control, all systems were inserted in CopyCutter E. coli EPI400 cells (LGC Biosearch Technologies, Teddington, England). These cells have the ability to lower the plasmid copy number, which helps to reduce leaky expression levels of the toxic genes. This extra layer showed to be relevant, as transformation of toxin-carrying systems in E. coli NEB5α cells did not result in any transformants. The use of this strain has the additional advantage that the same plasmid can be used for both cloning and expression purposes. While non-induced, the low copy number helps for successful cloning of the more problematic toxins, but at the same time, protein production can be attempted after inducing the copy number without the need to reclone the toxin in a higher copy number plasmid (which may be problematic).
All three different layers of control mentioned above were combined to increase cloning efficiency. When gene expression is desired, the toxin production can be induced on transcriptional, translational and replicational levels.

2.3. Cloning Efficiency of the Different Systems

Regulation through the use of both the naringenin-inducible PfdeA promoter and the vitamin B12 riboswitch led to successful cloning of most of the toxic genes: for all toxins except the highly toxic VcParE2, mutation-free transformants were obtained in E. coli CopyCutter EPI400 cells (Table 1). This was confirmed by colony PCR and Sanger sequencing.
The stronger tac promoter (Ptac) was combined with the vitamin B12 riboswitch to evaluate the effect of producing more toxin proteins per cell. Here, only clones of non-toxic mutants and the weak toxin EcMazF could be obtained.
However, inserting all toxins in a system harboring Ptac and the theophylline riboswitch appeared to be more successful. For this system, a combination of mutation-free toxins (EcMazF, EcParE2, VcHigB2) and toxins that carry point mutations, albeit still significantly toxic (P1Doc, FCcdB, barnase), as shown later, were successfully cloned. These mutations include Doc N69H and the double mutant A32T/A63V. For CcdB, we recovered the S22I point mutant and for barnase either I52T or S93R. Later, the point mutants DocN69H, CcdBS22I and barnaseI52T will be used for further experiments on this system. From now on, we will refer to them as P1Doc*, FCcdB* and barnase*.
The higher success rate for cloning toxic genes in the Ptac—RStheo system compared to Ptac—RSB12 indicates that the theophylline riboswitch suppresses translation in a more efficient manner than the vitamin B12 riboswitch.
Cloning of VcParE2 failed for all the above strategies, as frameshift mutations were repeatedly encountered. Therefore, the VcParE2 gene was inserted in a system combining the efficient theophylline riboswitch with the tighter controlled and weaker arabinose-inducible promoter (PBAD). This ultimately led to the successful cloning of a mutation-free VcParE2 in the absence of its cognate ParD2 antitoxin.

2.4. Assessing Toxicity upon Inducing Gene Expression

2.4.1. Combination of the PfdeA Promoter with the RSB12 Riboswitch

During the OFF-state (Figure 2A, black bars on Figure 3), where vitamin B12 was added to the plates and gene expression was inhibited, the growth of all toxin-harboring cultures was around 109 CFU/mL. This is also what we would expect for overnight-grown E. coli in optimal growth conditions [36]. This indicates that growth when gene expression of the toxins is not induced reaches the optimal conditions. Inducing gene expression (Figure 2B, grey bars on Figure 3), by adding naringenin and removing vitamin B12 from the plate media, resulted in a detrimental effect on the host growth for most of the toxins (P1Doc, VcHigB2, barnase and FCcdB). This caused a reduction of growth with a factor of 104 for barnase, P1Doc and VcHigB2 and a factor of 103 for FCcdB (Table S1). In contrast, no effect on growth was observed upon induction of EcMazF or EcParE2. For some potent toxins (such as P1Doc, VcHigB2, barnase and FCcdB), only a few proteins are enough to kill the cell, while for other toxins (such as EcMazF and EcParE2) overexpression of the toxin appears to be needed to intervene with cell viability. This all depends on the mode of action of the toxins as well as the stoichiometry of interaction between the toxin and its target inside the cell. In case of MazF, the reduced toxic effect can additionally be explained by the production of the MazE antitoxin by the E. coli strain, inhibiting MazF’s action. When comparing Figure 2C with Figure 2D, where gene expression was only partly induced, we can conclude that adding naringenin to the plate had a more significant effect on cell growth compared to the removal of vitamin B12 from the plate. This suggests the minor role of the vitamin B12 riboswitch in this strategy. For controls, P1DocH66Y and EcMazFE24A, no reduction in growth was observed over the different plates.

2.4.2. Combination of the Ptac Promoter with the RStheo Riboswitch

The same screen was performed for the Ptac—theophylline system (Figure 4 and Figure 5), where we observed a dramatic effect on cell growth for all toxins when supplementing inducing agents IPTG and theophylline to the LB ampicillin plates (Figure 4A,B). This decrease in growth corresponds to an average of 104 orders of magnitude for P1Doc* and EcMazF, for P1DocH66Y and EcParE2 only a 10- to 100-fold reduction, for EcMazFE24A and FCcdB approximately 3 orders of magnitude and for VcHigB2 and barnase the biggest effect is observed with a 105-fold decrease compared to the OFF-state (Table S2). When comparing the sole effect of IPTG and theophylline, one can conclude that their contribution to growth reduction is notable and comparable (which was not the case for the PfdeA-RSB12 system). Additionally, they clearly work synergistically as the combined effect of both agents is much higher than when applied separately (Figure 4C,D). In contrast to the PfdeA-RSB12 system, a clear toxic effect is observed for EcMazF and EcParE2 when both IPTG and theophylline are combined, most likely because the strong inducible tac promoter ensures higher transcription levels. For the controls, however, a decrease in growth was also observed, with a greater effect for EcMazFE24A than for P1DocH66Y. This different observation might be due to the nature of these mutants. While the P1DocH66Y mutant has a point mutation in one of the catalytic residues, the EcMazFE24A mutant is inoperative in recognizing its mRNA substrate sites [13,37]. This mutation increases the cell’s viability drastically compared to wild-type MazF with ten times reduced RNase activity [12]. However, this activity is possibly still high enough once a sufficient number of proteins is produced to impact the host’s survival upon overexpression under the control of the strong Ptac.
The theophylline riboswitch was shown in the past to tightly control translation of proteins with very low leakiness [26,38]. This agrees with our own result, where the theophylline riboswitch seems to work more stringently than the vitamin B12 riboswitch. The system works best in combination with the strong inducible Ptac. Nevertheless, we must consider that this promoter can have up to 2% leaky expression [8], which might cause difficulties when working with extremely toxic genes.

2.4.3. Combination of the PBAD Promoter with the RStheo Riboswitch

One way to circumvent this issue of leakiness is by using a weaker inducible promoter, namely PBAD, having a 20-fold decrease in leaky expression [6]. When combining the theophylline riboswitch with the weaker arabinose promoter, the reduction in growth for E. coli EPI400 harboring pJYP4_VcParE2 upon induction of gene expression was in the range of 104 orders of magnitude (Figure 6). This combination seems to surpass all other systems, as the potent VcParE2 was successfully cloned only under these stringent conditions.

2.5. Applicability of the Ptac—Theophylline System for Protein Production

Next, we wanted to know if our multi-layer control systems also allow for successful overexpression and protein production after induction. We chose the Ptac—theophylline system as this combines the strongest promoter with the most successful riboswitch. We first evaluated the use of the E. coli EPI400 CopyCutter strain to increase the copy number of the expression plasmid upon induction. Depending on the plasmid used, a 2- to 20-fold increase in copy number is typically reported [7]. We therefore determined this increase for pJYP2_doc* and pJYP2_docH66Y via qPCR. In both cases, we observed an approximately 50-fold increase in plasmid copy number upon induction (see Supplementary qPCR results for details: Figure S2 and Tables S3–S6). This not only allows for plasmid preparation at higher yields, but also suggests that useful overexpression may be obtained.
To assess the levels of protein synthesis in the Ptac—theophylline system, small-scale expression tests were performed for C-terminally histidine-tagged P1Doc* and P1DocH66Y. For non-toxic P1DocH66Y, a clear signal can be detected on western blot four hours after induction, suggesting that significant overexpression is obtained (Figure 7). For P1Doc* on the other hand, no signal was obtained in western blot. Most likely, this is caused by the activity of the protein itself: by directly inhibiting translation, it inhibits its own production. Given that P1Doc is an enzyme, even a few molecules are likely sufficient to shut down the translation machinery. When monitoring the growth of E. coli EPI400 cells containing pJYP2_doc* and pJYP2_docH66Y, induction of expression via IPTG, theophylline and CopyCutter Induction Solution did not affect the growth of cells harboring plasmids encoding P1DocH66Y, and also the growth of non-induced cells harboring P1Doc* was not affected (Figure S1). In contrast, upon induction of P1Doc*, growth initially slowed down but caught up afterwards, likely due to mutations in doc, as we also observed in the spot tests (Figure S1).
To assess the potential of the Ptac—RStheo system for protein production, large-scale overexpression of his-tagged P1Doc and P1DocH66Y was attempted. Using material from larger volumes allowed western blot signals to be obtained for both P1Doc* and P1DocH66Y. The signal for P1Doc* remained nonetheless significantly weaker than that for the non-toxic variant (Figure 8). Hence, overexpression and purification in reasonable amounts are difficult when the protein of interest directly targets the transcription or translation machinery. Consequently, our approach is still most useful for cloning particularly potent toxins and performing in vivo activity assays but less so for producing protein for biochemical or biophysical studies.

3. Conclusions

We evaluated different controlling systems for the cloning of highly toxic genes, minimizing leaky expression to almost zero. It must be noted that this is the first time that the highly toxic barnase and VcParE2 were cloned in the absence of their cognate inhibitors barstar and VcParD2, respectively. However, for overexpression and production purposes of the toxin protein, the yields remain low. However, with the evolving techniques, the amount might be sufficient for downstream study experiments on the toxin protein. Although this system was evaluated for toxins for which antitoxins exist, the antitoxins are not needed in this strategy, allowing the expansion of this strategy for all toxins. We designed a model system to efficiently clone toxic or unstable genes which might be optimized to overexpress and produce toxic/unstable proteins in the future.

4. Materials and Methods

4.1. Cloning and Transformation

4.1.1. PfdeA Promoter

The pET22b expression vector was modified by inserting the FdeR transcriptional activator and promoter–operator region (PfdeAfdeO) followed by a vitamin B12 riboswitch (RSB12) into the HpaI and XhoI site (Table S7). The resulting pJYP1 (Accession Number: OQ725380) vector contains a BglII restriction site downstream of the riboswitch to allow toxin cloning. Synthetic genes coding for different toxins were obtained via Twist Bioscience (San Francisco, CA, USA). The primers used for amplification of the different toxins prior to cloning are listed in Table 2. A polyhistidine-tag was placed N- or C-terminally, based on known purification strategies for the respective toxins (Table 3). The lyophilized synthetic DNA was dissolved to a concentration of 20 ng/μL. Using HiFi DNA assembly (New England Biolabs, Ipswich, MA, USA), all toxin genes were cloned in pJYP1 digested with BglII, resulting in different pJYP1_toxin vectors. CaCl2-competent EPI400 E. coli cells (mcrA ∆(mrr-hsdRMS-mcrBC) φ80dlacZ∆M15 ∆lacX74 recA1 endA1 araD139 ∆(ara, leu)7697 galU galK λ–rpsL nupG tonA ∆pcnB dhfr) were then transformed with the assembled DNA [39]. The competent cells were thawed on ice before adding 2 μL of the assembled DNA mixture. After 30 min incubation on ice, a heat shock was performed at 42 °C for 1 min. The transformation mixture was diluted by adding 1 mL of LB medium (Bertani, 1951) supplemented with 50 nM vitamin B12 after which it was incubated while shaking at 37 °C for 4 h to allow phenotypic expression. Hundred μL of the culture was spread on an LB plate supplemented with 100 μg/mL of ampicillin and 50 nM of vitamin B12 before overnight incubation at 37 °C. Transformants were first tested for the presence of an intact toxin by comparing the growth of the colonies on both LB agar plates supplemented with 100 µg/mL ampicillin and 50 nM of vitamin B12 and LB agar plates supplemented with 100 µg/mL ampicillin and 100 µg/mL naringenin as inducer. The colonies that showed reduced growth for the latter conditions were further screened through sequencing from miniprepped plasmids. The plasmids were recovered by preparing an overnight culture of E. coli EPI400 (pJYP1_toxin) in LB supplemented with 100 μg/mL of ampicillin and 50 nM vitamin B12. This was used to inoculate 10 mL of fresh LB with 100 μg/mL of ampicillin, 1× CopyCutter Induction Solution (LGC Biosearch Technologies, Teddington, England) and 50 nM vitamin B12, which was added to reach an OD600 of 0.2. This culture was incubated for 4 h at 37 °C shaking, after which plasmid DNA was purified following the Monarch® Plasmid Miniprep Kit (NEB, Ipswich, MA, USA). Sequencing was performed using primers Seq_Primer25 (5′-ttgagcctggccatgacaac-3′) and Seq_Primer26 (5′-ccagcctacacgggagagtg-3′).

4.1.2. Tac Promoter

Restriction digestion with BglII and XhoI (NEB) for 1 h at 37 °C was performed to remove the T7 promoter and lac operator of vector pET22b. Synthetic DNA fragments comprising the tac promoter (Ptac) and lac operator followed by the theophylline (RStheo) or vitamin B12 (RSB12) riboswitch upstream of a C- or N-terminal his-tagged toxin gene and 25 bp overlap with the pET22b vector for Gibson assembly cloning were designed (Table 3 and Table S7) and ordered via Twist Bioscience (San Francisco, CA, USA). Gibson assembly was performed to insert the construct at the BglII and XhoI restriction sites of vector pET22b, resulting in the pJYP2_toxin and pJYP3_toxin constructs, for the theophylline and vitamin B12 riboswitch, respectively. The assembled DNA was subsequently transformed into CaCl2-competent E. coli EPI400 cells, as described above. An LB agar plate supplemented with 100 µg/mL ampicillin was plated with 100 µL of the transformation product and incubated overnight at 37 °C. A first screening for positive transformants was performed by comparing the growth of the colonies on both LB agar plates supplemented with 100 µg/mL ampicillin and LB agar plates supplemented with 100 µg/mL ampicillin, 0.5 mM IPTG and 2 mM theophylline (60 mg/mL stock dissolved in 200 mM NaOH). The colonies that showed reduced growth for the latter conditions were further screened by colony PCR and sequencing, using primers Seq_Primer37 (5′-gatcttccccatcggtgatg-3′) and Seq_Primer38 (5′-gcagcagccaactcagcttc-3′).

4.1.3. Arabinose Promoter

Analogously to the tac system, a synthetic construct containing araC and the C-terminally his-tagged Vibrio cholerae parE2 toxin gene under the control of PBAD in combination with the theophylline riboswitch (Table 3 and Table S7) was cloned in the pET22b vector digested with BglII/XhoI.

4.2. Spot Test

An overnight culture of the positive transformants was prepared in 5 mL of LB medium supplemented with 100 µg/mL ampicillin (and 50 nM of vitamin B12 for the RSB12 constructs). The next day, a serial dilution of the overnight culture was made in LB medium (100–10−6). Five µL of each dilution was spotted on square 50 mL LB plates supplemented with 100 µg/mL ampicillin (non-induced) and on LB agar plates supplemented with 100 µg/mL ampicillin, 2 mM theophylline and 0.5 mM IPTG (induced) or either one of each inducing agent (partly induced) for the Ptac—RStheo strategy. For the PfdeA—RSB12 strategy, spots were placed on LB agar plates supplemented with 100 µg/mL ampicillin and 50 nM vitamin B12 (non-induced) and LB agar plates supplemented with 100 µg/mL ampicillin and 100 µg/mL naringenin (induced), as well as LB agar plates with only 100 µg/mL ampicillin, or with both 50 nM vitamin B12 and 100 µg/mL naringenin (partly induced).

4.3. Plate Reader Experiment

Overnight cultures were prepared for E. coli EPI400 pJYP2_doc* and pJYP2_docH66Y in 5 mL LB medium supplemented with 100 µg/mL ampicillin. Cultures were brought to an OD of 2. A 96-well plate was prepared by adding 2 µL of the cultures and 178 µL of LB ampicillin medium. The OD600 was measured every 20 min using the Biotek Synergy H1 (BioSPX, Abcoude, The Netherlands) microplate reader while shaking at 425 cpm—37 °C. Once an OD of approximately 0.2 was measured, 2 mM theophylline, 0.5 mM IPTG and 1× CopyCutterTM Induction Solution was added for the induced samples, and an equal volume of LB medium was added for the non-induced samples. Cultures were further grown in the same conditions for a total of 16 h.

4.4. Expression Test

Expression was first tested on a small scale. Individual colonies of E. coli EPI400 carrying the pJYP2_doc* and pJYP2_docH66Y plasmid were picked to start an overnight preculture of 10 mL of LB enriched with 100 µg/mL ampicillin at 37 °C. A main culture of 80 mL of LB supplemented with 100 µg/mL ampicillin, 1× CopyCutterTM Induction Solution and a 20-fold dilution of the preculture was grown until OD600 = 1. Next, protein expression was induced by adding 0.5 mM IPTG and 2 mM theophylline. Samples of 10 mL collected before and 4 h after induction were centrifuged for 9 min at 2500× g, and the pelletized cells were resuspended in 200 µL B-PERTM bacterial protein extraction reagent (ThermoFisher, Waltham, MA, USA) After 10 min of incubation, the cell lysis product was centrifuged for 5 min at 17,000× g. The resulting supernatant was used for SDS-PAGE and anti-his-tag Western blot analysis [40,41]. For western blot, proteins were transferred from the SDS-PAGE gel to a blotting membrane (Trans-Blot Turbo Transfer System, Bio-Rad, Hercules, CA, USA) by applying 25V for 5 min. The membrane was blocked for 45 min in 5% milk powder in 1X TBS, followed by a 1 h incubation with 10 µL mouse anti-his (Bio-Rad) in 10 mL 5% milk in 1X TBS. After washing the membrane with 1X TBS, a second incubation step of 40 min was performed with goat-anti-mouse IgG (Merck, Darmstadt, Germany) in 10 mL 5% milk in 1X TBS. Subsequently, the membrane was washed 3 times with 1X TBS, and protein visualization was obtained by a final 15 min incubation of the membrane in 10 mL of western blot buffer (100 mM Tris, 50 mM MgCl2, 100 mM NaCl) combined with 50 µL NBT-BCIP substrate.
For large-scale protein purification, an overnight preculture containing 250 mL of LB, 100 µg/mL ampicillin and a picked colony was grown at 37 °C. A 50-fold dilution of this preculture was used to inoculate 12 L of the main culture (12X 1 L LB enriched with 100 mg/mL ampicillin and 1× CopyCutterTM Induction Solution). The main culture was grown at 37 °C until OD600 = 0.8, after which 0.5 mM IPTG and 2 mM theophylline were added to induce protein expression. Cultures were grown for 4 h at 28 °C, and cells were harvested by centrifugation for 15 min 6200 g. The resulting pellet was dissolved in 20 mM Tris pH 8, 500 mM NaCl supplemented with a protease inhibitor (cOmpleteTM ULTA tablets, EDTA free, Roche, Basel, Switzerland), flash-frozen using liquid nitrogen and stored at −80 °C.

4.5. qPCR

Similar to Anindyajati et al., qPCR was performed to determine the primer efficiency [42]. Primer sets that target (1) the origin of replication (ori) in pET22b and (2) the d-1-deoxyxylulose 5-phosphate synthase gene (dxs) in the E. coli chromosome (Table 4) were used for qPCR on two technical replicates of the template with concentrations ranging from 0.00002 to 0.02 ng/µL (pET22b) and 0.00002 to 2 ng (genomic DNA). EPI400 E. coli chromosome was isolated with the genomic DNA preparation kit (Qiagen, Hilden, Germany), and pET22b was extracted using the Monarch® Plasmid Miniprep Kit (NEB, Ipswich, MA, USA). Primer efficiency (E) was determined by applying equation 1 after fitting a regression curve through the obtained Ct values as a function of the log of the starting quantity.
E = 10 1 / s l o p e
Cell lysates from four overnight cultures of EPI400 E. coli cells carrying pJYP2-doc* and pJYP2-docH66Y grown in the absence (non-induced) and presence (induced) of 1× CopyCutter Induction Solution were extracted as follows: 1 mL of overnight cell culture at OD600 = 2 was centrifuged for 1 minute at 16,000× g. Hereafter, the pellet was resuspended in 1 mL of milli-Q water, incubated at 95 °C for 10 min and again centrifuged at 16,000× g for 2 minutes. The resulting supernatant was collected, and a 10-fold dilution was prepared in milli-Q water for qPCR. A 1 µL volume of each 10-fold dilution was combined with 2× GoTaq qPCR Master Mix (Promega) and both ori and dxs primers in separate reactions. For each condition, 6 replicates and 2 negative controls were subjected to the following amplification: 5.5 min at 95 °C, 40 cycles consisting of 10 s denaturation at 95 °C and 30 s annealing at 55 °C.
To gain an idea of how much more plasmid is present in the induced state compared to the non-induced state, the ratio of plasmid to chromosome per cell (P/C) was calculated by applying following equation:
N u m b e r   o f   p l a s m i d N u m b e r   o f   c h r o m o s o m e = E C C t C E P C t P
Here, EC represents the primer efficiency of the primer set targeting the chromosome (dxs), CtC the threshold value measured with the dxs primers, EP the primer efficiency of the primer set targeting the plasmid (ori) and CtP the threshold value measured with the ori primers. To quantify the effect of induction with CopyCutter Induction Solution, P/C values from the induced state were divided by the ones from the non-induced state for pJYP2_doc* and pJYP2_docH66Y.

4.6. Protein Purification

The resuspended pellets from 12 L of cell culture were thawed and DNase I (50 µg/mL) and MgCl2(5 mM) were added. Cells were lysed using the cell cracker at 20 KPSI, and the resulting cell lysate was centrifuged at 46,000× g. The supernatant was filtered through a 0.45 µm filter and loaded on a 1 mL HisTrap HP column (Cytiva, Marlborough, MA, USA) equilibrated with 20 mM Tris pH 8, 500 mM NaCl. A step gradient of 20 mM Tris pH 8, 500 mM NaCl, 1 M imidazole (0–2–5–10–20–50–100%, 3 column volumes each) was applied. The progress of purification was visualized with SDS-PAGE and anti-his-tag Western blot.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/toxins15080508/s1, Table S1: overview of toxicity levels for the PfdeA-RSB12 strategy; Table S2: overview of toxicity levels for the Ptac-RStheo strategy; Figure S1: OD profile of E. coli EPI400 CopyCutter cells carrying either the plasmids pJYP1_doc or pJYP2_docH66Y; Supplementary qPCR results containing Figure S2: qPCR result for determination of plasmid efficiency; Table S3: PCR efficiency values (E) for the plasmid-specific ori primers and the genome-specific dxs primers; Table S4: Threshold cycle (Ct) values determined by qPCR using (A) the plasmid-specific ori primers and (B) the genome specific dxs primers; Table S5: P/C values calculated from qPCR performed on the cell lysate of E. coli EPI400 cells that carry pJYP2_doc and pJYP2_docH66Y in non-induced state (NI) and induced with CCIS (I); Table S6: Ratio of the Doc and DocH66Y P/C values in induced and non-induced state; Table S7: DNA sequences of the synthetic constructs.

Author Contributions

Conceptualization, H.D.G., P.D.B., R.L., J.V. and Y.G.; Methodology, J.V. and Y.G.; Validation, J.V. and Y.G.; Formal Analysis, J.V. and Y.G.; Investigation, J.V. and Y.G.; Resources, H.D.G. and R.L.; Writing—Original Draft Preparation, J.V.; Writing—Review and Editing, Y.G., R.L., H.D.G. and P.D.B.; Visualization, Y.G. and J.V.; Supervision, H.D.G. and R.L.; Project Administration, J.V. and Y.G.; Funding Acquisition, R.L. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by grants G.0226.17N and G003320N from FWO-Vlaanderen. Y.G. acknowledges the receipt of a personal PhD mandate from FWO-Vlaanderen (grants 1164620N and 1164622N).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The pJYP1 plasmid sequence is submitted to GenBank with Accession Number OQ725380 and Addgene (Addgene Plasmid #202406).

Acknowledgments

We thank Indra Bervoets for her support and critical reading of the manuscript.

Conflicts of Interest

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

  1. Sezonov, G.; Joseleau-Petit, D.; D’Ari, R. Escherichia coli physiology in Luria-Bertani broth. J. Bacteriol. 2007, 189, 8746–8749. [Google Scholar] [CrossRef] [PubMed]
  2. Pope, B.; Kent, H.M. High efficiency 5 min transformation of Escherichia coli. Nucleic Acids Res. 1996, 24, 536–537. [Google Scholar] [CrossRef] [PubMed]
  3. Rosano, G.L.; Ceccarelli, E.A. Recombinant protein expression in Escherichia coli: Advances and challenges. Front. Microbiol. 2014, 5, 172. [Google Scholar] [CrossRef] [PubMed]
  4. Bernard, P.; Couturier, M. Cell killing by the F plasmid CcdB protein involves poisoning of DNA-topoisomerase II complexes. J. Mol. Bio. 1992, 226, 735–745. [Google Scholar] [CrossRef]
  5. Bunker, R.D.; McKenzie, J.L.; Baker, E.N.; Arcus, V.L. Crystal structure of PAE0151 from Pyrobaculum aerophilum, a PIN-domain (VapC) protein from a toxin-antitoxin operon. Proteins 2008, 72, 510–518. [Google Scholar] [CrossRef]
  6. Guzman, L.M.; Belin, D.; Carson, M.J.; Beckwith, J. Tight regulation, modulation, and high-level expression by vectors containing the arabinose PBAD promoter. J. Bacteriol. 1995, 177, 4121–4130. [Google Scholar] [CrossRef]
  7. CopyCutterTM EPI400TM. Available online: https://www.yumpu.com/en/document/read/37026343/protocol-for-copycuttertm-epi400tm-electrocompetent-e-coli- (accessed on 4 April 2023).
  8. Jacob, F.; Monod, J. Genetic regulatory mechanisms in the synthesis of proteins. J. Mol. Biol. 1961, 3, 318–356. [Google Scholar] [CrossRef]
  9. Lanzer, M.; Bujard, H. Promoters largely determine the efficiency of repressor action. Proc. Natl. Acad. Sci. USA 1988, 85, 8973–8977. [Google Scholar] [CrossRef]
  10. Valdez-Cruz, N.A.; Caspeta, L.; Pérez, N.O.; Ramirez, O.T.; Trujillo-Roldan, M.A. Production of recombinant proteins in E. coli by the heat inducible expression system based on the phage lambda pL and/or pR promoters. Microb. Cell Fact. 2010, 19, 9–18. [Google Scholar] [CrossRef]
  11. Guo, J.; Jia, R. A novel inducible expression system for the functional study of toxic gene in bacteria. World J. Microbiol. Biotechnol. 2014, 30, 1527–1531. [Google Scholar] [CrossRef]
  12. Li, G.Y.; Zhang, Y.; Chan, M.C.Y.; Mal, T.K.; Hoeflich, K.P.; Inouye, M.; Ikura, M. Characterization of dual substrate binding sites in the homodimeric structure of Escherichia coli mRNA interferase MazF. J. Mol. Bio. 2006, 357, 139–150. [Google Scholar] [CrossRef]
  13. Magnuson, R.; Yarmolinsky, M.B. Corepression of the P1 addiction operon by Phd and Doc. J. Bacteriol. 1998, 180, 6342–6351. [Google Scholar] [CrossRef] [PubMed]
  14. Wieland, M.; Hartig, J. Improved aptazyme design and in vivo screening enable riboswitching in bacteria. Angew. Chem. Int. Ed. Engl. 2008, 47, 2604–2607. [Google Scholar] [CrossRef] [PubMed]
  15. Westbrook, A.M.; Lucks, J.B. Achieving large dynamic range control of gene expression with a compact RNA transcription-translation regulator. Nucleic Acids Res. 2017, 45, 5614–5624. [Google Scholar] [CrossRef] [PubMed]
  16. Li, H.; Hao, C.; Xu, D. Development of a novel vector for cloning and expressing extremely toxic genes in Escherichia coli. Electron. J. Biotechnol. 2017, 30, 88–94. [Google Scholar] [CrossRef]
  17. Minaba, M.; Kato, Y. High-yield, zero-leakage expression system with a translational switch using site-specific unnatural amino acid incorporation. Appl. Environ. Microbiol. 2014, 80, 1718–1725. [Google Scholar] [CrossRef]
  18. Nudler, E.; Mironov, A.S. The riboswitch control of bacterial metabolism. Trends Biochem. Sci. 2004, 29, 11–17. [Google Scholar] [CrossRef]
  19. Mandal, M.; Breaker, R. Adenine riboswitches and gene activation by disruption of a transcription terminator. Nat. Struct. Mol. Biol. 2004, 11, 29–35. [Google Scholar] [CrossRef]
  20. Aufrère, R.; Tempête, M.; Bohin, J.P. Regulation of expression of the gene for vitamin B12 receptor cloned on a multicopy plasmid in Escherichia coli. Mol. Gen. Genet. 1986, 205, 358–365. [Google Scholar] [CrossRef]
  21. Verhounig, A.; Karcher, D.; Bock, R. Inducible gene expression from the plastid genome by a synthetic riboswitch. Proc. Natl. Acad. Scie. USA 2010, 107, 6204–6209. [Google Scholar] [CrossRef]
  22. Kato, Y. Extremely low leakage expression systems using dual transcriptional-translational control for toxic protein production. Int. J. Mol. Sci. 2020, 21, 705. [Google Scholar] [CrossRef] [PubMed]
  23. Morra, R.; Shankar, J.; Robinson, C.J.; Halliwell, S.; Butler, L.; Upton, M.; Hay, S.; Micklefield, J.; Dixon, N. Dual transcriptional-translational cascade permits cellular level tuneable expression control. Nucleic Acids Res. 2016, 44, e21. [Google Scholar] [CrossRef] [PubMed]
  24. Lee, Y.J.; Kim, S.J.; Moon, T.S. Multilevel regulation of bacterial gene expression with the combined STAR and antisense RNA system. ACS Synth. Biol. 2018, 7, 853–865. [Google Scholar] [CrossRef] [PubMed]
  25. O’Connor, C.D.; Timmis, K.N. Highly repressible expression system for cloning genes that specify potentially toxic proteins. J. Bacteriol. 1987, 169, 4457–4462. [Google Scholar] [CrossRef] [PubMed]
  26. Wang, X.; Fang, C.; Wang, Y.; Shi, X.; Yu, F.; Xiong, J.; Chou, S.; He, J. Systematic comparison and rational design of theophylline riboswitches for effective gene repression. Microbiol. Spectr. 2023, 11, e02752-22. [Google Scholar] [CrossRef]
  27. Fico, S.; Mahillon, J. TasA-tasB, a new putative toxin-antitoxin (TA) system from Bacillus thuringiensis pGI1 plasmid is a widely distributed composite mazE-doc TA system. BMC Genom. 2006, 7, 259. [Google Scholar] [CrossRef]
  28. Zhang, Y.; Zhang, J.; Hoeflich, K.P.; Ikura, M.; Qing, G.; Inouye, M. MazF cleaves cellular mRNAs specifically at ACA to block protein synthesis in Escherichia coli. Mol. Cell 2003, 12, 913–923. [Google Scholar] [CrossRef]
  29. Christensen-Dalsgaard, M.; Gerdes, K. Two higBA loci in the Vibrio cholerae superintegron encode mRNA cleaving enzymes and can stabilize plasmids. Mol. Microbiol. 2006, 62, 397–411. [Google Scholar] [CrossRef]
  30. Cruz, J.W.; Rothenbacher, F.P.; Maehigashi, T.; Lane, W.S.; Dunham, C.M.; Woychik, N.A. Doc toxin is a kinase that inactivates elongation factor Tu. J. Biol. Chem. 2014, 289, 7788–7798. [Google Scholar] [CrossRef]
  31. Bahassi, E.M.; O’Dea, M.H.; Allali, N.; Messens, J.; Gellert, M.; Couturier, M. Interactions of CcdB with DNA gyrase. Inactivation of GyrA, poisoning of the gyrase-DNA complex, and the antidote action of CcdA. J. Biol. Chem. 1999, 274, 10936–10944. [Google Scholar] [CrossRef]
  32. Yuan, J.; Sterckx, Y.; Mitchenall, L.A.; Maxwell, A.; Loris, R.; Waldor, M.K. Vibrio cholerae ParE2 poisons DNA gyrase via a mechanism distinct from other gyrase inhibitors. J. Biol. Chem. 2010, 285, 40397–40408. [Google Scholar] [CrossRef] [PubMed]
  33. Hallez, R.; Geeraerts, D.; Sterckx, Y.; Mine, N.; Loris, R.; Van Melderen, L. New toxins homologous to ParE belonging to three-component toxin-antitoxin systems in Escherichia coli O157:H7. Mol. Microbiol. 2010, 76, 719–732. [Google Scholar] [CrossRef] [PubMed]
  34. Hartley, R.W. Barnase and barstar: Two small proteins to fold and fit together. Trends Biochem. Sci. 1989, 14, 450–454. [Google Scholar] [CrossRef]
  35. De Paepe, B.; Maertens, J.; Vanholme, B.; De Mey, M. Modularization and response curve engineering of a naringenin-responsive transcriptional biosensor. ACS Synth. Biol. 2008, 7, 1303–1314. [Google Scholar] [CrossRef]
  36. Tuttle, A.R.; Trahan, N.D.; Son, M.S. Growth and maintenance of Escherichia coli laboratory strains. Curr. Protoc. 2021, 1, e20. [Google Scholar] [CrossRef]
  37. Zorzini, V.; Mernik, A.; Lah, J.; Sterckx, Y.G.; De Jonge, N.; Garcia-Pino, A.; De Greve, H.; Versées, W.; Loris, R. Substrate recognition and activity regulation of the Escherichia coli mRNA endonuclease MazF. J. Biol. Chem. 2016, 291, 10950–10960. [Google Scholar] [CrossRef]
  38. Nakahira, Y.; Ogawa, A.; Asano, H.; Oyama, T.; Tozawa, Y. Theophylline-dependent riboswitch as a novel genetic tool for strict regulation of protein expression in cyanobacterium Synechococcus elongatus PCC 7942. Plant Cell Physiol. 2013, 54, 1724–1735. [Google Scholar] [CrossRef]
  39. Hanahan, D. Studies on transformation of Escherichia coli with plasmids. J. Mol. Biol. 1983, 166, 557–580. [Google Scholar] [CrossRef]
  40. Laemmli, U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227, 680–685. [Google Scholar] [CrossRef] [PubMed]
  41. Towbin, H.; Staehelin, T.; Gordon, J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc. Natl. Acad. Sci. USA 1979, 76, 4350–4354. [Google Scholar] [CrossRef]
  42. Anindyajati; Artarini, A.A.; Riani, C.; Retnoningrum, D.S. Plasmid copy number determination by quantitative polymerase chain reaction. Sci. Pharm. 2016, 84, 89–101. [Google Scholar] [CrossRef] [PubMed]
  43. Lee, C.; Kim, J.; Shin, S.G.; Hwang, S. Absolute and relative qPCR quantification of plasmid copy number in Escherichia coli. J. Biotechnol. 2006, 123, 273–280. [Google Scholar] [CrossRef] [PubMed]
Figure 1. Schematic overview of transcriptional and translational layers of control for the four systems developed in this study. Different promoters and riboswitches were combined to control the toxin’s (red) gene expression. (A) PfdeA-RSB12 combination. The naringenin-inducible promoter PfdeA in light blue is positively regulated by the FdeR activator (grey) in presence of naringenin and is combined with the negatively regulated vitamin B12 riboswitch (RSB12, green). Only in absence of vitamin B12, the ribosome binding site (RBS, orange) is accessible for ribosome binding. (B) Ptac-RSB12 combination. The IPTG-inducible tac promoter (Ptac) in light purple is repressed by binding of the LacI repressor (brown) to the lac operator (lacO, purple) in absence of IPTG. Presence of IPTG allows transcription initiation. This is combined with the B12 riboswitch. (C) Ptac-RStheo combination. The lacI/lacO operator system is combined with the positively regulated synthetic theophylline riboswitch (RStheo, yellow). Presence of theophylline (blue) alters the riboswitch conformation, allowing access to the RBS and therefore translation. (D) PBAD-RStheo combination. The arabinose-inducible promoter PBAD (light green) is positively regulated through the binding of the AraC activator (magenta) to the I1 and I2 sites when bound to arabinose (turquoise). Combination with the RStheo allows tight regulation of the toxic gene.
Figure 1. Schematic overview of transcriptional and translational layers of control for the four systems developed in this study. Different promoters and riboswitches were combined to control the toxin’s (red) gene expression. (A) PfdeA-RSB12 combination. The naringenin-inducible promoter PfdeA in light blue is positively regulated by the FdeR activator (grey) in presence of naringenin and is combined with the negatively regulated vitamin B12 riboswitch (RSB12, green). Only in absence of vitamin B12, the ribosome binding site (RBS, orange) is accessible for ribosome binding. (B) Ptac-RSB12 combination. The IPTG-inducible tac promoter (Ptac) in light purple is repressed by binding of the LacI repressor (brown) to the lac operator (lacO, purple) in absence of IPTG. Presence of IPTG allows transcription initiation. This is combined with the B12 riboswitch. (C) Ptac-RStheo combination. The lacI/lacO operator system is combined with the positively regulated synthetic theophylline riboswitch (RStheo, yellow). Presence of theophylline (blue) alters the riboswitch conformation, allowing access to the RBS and therefore translation. (D) PBAD-RStheo combination. The arabinose-inducible promoter PBAD (light green) is positively regulated through the binding of the AraC activator (magenta) to the I1 and I2 sites when bound to arabinose (turquoise). Combination with the RStheo allows tight regulation of the toxic gene.
Toxins 15 00508 g001
Figure 2. Spot test of serial diluted toxins on plates with or without inducing agents for the PfdeA—RSB12 strategy. E. coli EPI400 harboring the successfully cloned toxins P1Doc, P1DocH66Y, EcMazF, EcMazFE24A, EcParE2, VcHigB2, barnase and FCcdB on the pJYP1 vector was spotted on LB agar plates supplemented with ampicillin and additionally vitamin B12 (A, OFF-state) or naringenin (B, ON-state) or a combination of both (C, partly induced) or none of the additional agents (D, partly induced).
Figure 2. Spot test of serial diluted toxins on plates with or without inducing agents for the PfdeA—RSB12 strategy. E. coli EPI400 harboring the successfully cloned toxins P1Doc, P1DocH66Y, EcMazF, EcMazFE24A, EcParE2, VcHigB2, barnase and FCcdB on the pJYP1 vector was spotted on LB agar plates supplemented with ampicillin and additionally vitamin B12 (A, OFF-state) or naringenin (B, ON-state) or a combination of both (C, partly induced) or none of the additional agents (D, partly induced).
Toxins 15 00508 g002
Figure 3. Logarithmic normalized overview of cell growth observed for the PfdeA-RSB12 strategy. Colonies are counted from the spot test on different LB ampicillin plates for E. coli EPI400 harboring toxins P1Doc, P1DocH66Y, EcMazF, EcMazFE24A, EcParE2, VcHigB2, barnase and FCcdB. Raw colony count data were normalized to fraction survival for comparison of the OFF-state (vitamin B12 and no naringenin, black bars) to the ON-state (naringenin and no vitamin B12, grey bars).
Figure 3. Logarithmic normalized overview of cell growth observed for the PfdeA-RSB12 strategy. Colonies are counted from the spot test on different LB ampicillin plates for E. coli EPI400 harboring toxins P1Doc, P1DocH66Y, EcMazF, EcMazFE24A, EcParE2, VcHigB2, barnase and FCcdB. Raw colony count data were normalized to fraction survival for comparison of the OFF-state (vitamin B12 and no naringenin, black bars) to the ON-state (naringenin and no vitamin B12, grey bars).
Toxins 15 00508 g003
Figure 4. Spot test of serial diluted toxins on plates with or without inducing agents for the Ptac—RStheo strategy. E. coli EPI400 harboring the successfully cloned toxins P1Doc*, P1DocH66Y, EcMazF, EcMazFE24A, EcParE2, VcHigB2, barnase* and FCcdB* on the pJYP3 vector were spotted on LB agar plates supplemented with ampicillin (A, OFF-state) and additionally theophylline and IPTG (B, ON-state) or IPTG alone (C, partly induced) or theophylline alone (D, partly induced).
Figure 4. Spot test of serial diluted toxins on plates with or without inducing agents for the Ptac—RStheo strategy. E. coli EPI400 harboring the successfully cloned toxins P1Doc*, P1DocH66Y, EcMazF, EcMazFE24A, EcParE2, VcHigB2, barnase* and FCcdB* on the pJYP3 vector were spotted on LB agar plates supplemented with ampicillin (A, OFF-state) and additionally theophylline and IPTG (B, ON-state) or IPTG alone (C, partly induced) or theophylline alone (D, partly induced).
Toxins 15 00508 g004
Figure 5. Logarithmic normalized overview of cell growth observed for the Ptac—RStheo strategy. Colonies are counted from the spot test on different LB ampicillin plates for E. coli EPI400 harboring toxins P1Doc, P1DocH66Y, EcMazF, EcMazFE24A, EcParE2, VcHigB2, barnase and FCcdB. Raw colony count data were normalized to fraction survival for comparison of the OFF-state (no theophylline and no IPTG, black bars) to the ON-state (theophylline and IPTG, grey bars).
Figure 5. Logarithmic normalized overview of cell growth observed for the Ptac—RStheo strategy. Colonies are counted from the spot test on different LB ampicillin plates for E. coli EPI400 harboring toxins P1Doc, P1DocH66Y, EcMazF, EcMazFE24A, EcParE2, VcHigB2, barnase and FCcdB. Raw colony count data were normalized to fraction survival for comparison of the OFF-state (no theophylline and no IPTG, black bars) to the ON-state (theophylline and IPTG, grey bars).
Toxins 15 00508 g005
Figure 6. Spot test of serial diluted E. coli EPI400 harboring pJYP4_VcParE2 on plates with or without inducing agents for the PBAD—RStheo strategy. E. coli EPI400 harboring pJYP4_VcParE2 was spotted on (A, OFF-state) LB agar plates supplemented with ampicillin and (B, ON-state) theophylline and arabinose.
Figure 6. Spot test of serial diluted E. coli EPI400 harboring pJYP4_VcParE2 on plates with or without inducing agents for the PBAD—RStheo strategy. E. coli EPI400 harboring pJYP4_VcParE2 was spotted on (A, OFF-state) LB agar plates supplemented with ampicillin and (B, ON-state) theophylline and arabinose.
Toxins 15 00508 g006
Figure 7. Small-scale expression of P1Doc and P1DocH66Y using the Ptac—RStheo strategy. Samples of P1Doc* and P1DocH66Y before induction (BI) and four hours after induction (t = 4) were analyzed via 20% SDS-PAGE (left) and anti-histidine Western blot (right).
Figure 7. Small-scale expression of P1Doc and P1DocH66Y using the Ptac—RStheo strategy. Samples of P1Doc* and P1DocH66Y before induction (BI) and four hours after induction (t = 4) were analyzed via 20% SDS-PAGE (left) and anti-histidine Western blot (right).
Toxins 15 00508 g007
Figure 8. IMAC purification of P1DocH66Y (blue) and P1Doc* (red) using the Ptac—RStheo strategy. Fractions collected during IMAC elution (A,B) were analyzed through 20% SDS-PAGE (C,D) and anti-histidine Western blot (E,F). The blue and red arrows respectively indicate P1DocH66Y and P1Doc* (14.6 kDa).
Figure 8. IMAC purification of P1DocH66Y (blue) and P1Doc* (red) using the Ptac—RStheo strategy. Fractions collected during IMAC elution (A,B) were analyzed through 20% SDS-PAGE (C,D) and anti-histidine Western blot (E,F). The blue and red arrows respectively indicate P1DocH66Y and P1Doc* (14.6 kDa).
Toxins 15 00508 g008
Table 1. Overview of toxins cloned in four different gene expression systems. +: mutation-free clone; -: no clone; ~ : toxic clone with mutation; NT: not tested.
Table 1. Overview of toxins cloned in four different gene expression systems. +: mutation-free clone; -: no clone; ~ : toxic clone with mutation; NT: not tested.
ToxinsAccession Number UniprotPfdeA—RSB12Ptac—RSB12Ptac—RStheoPBAD—RStheo
P1DocQ06259 DOC_BPP1+- ~ NT
P1DocH66Y/+++NT
EcMazFP0AE70 MAZF_ECOLI+++NT
EcMazFE24A/+++NT
EcParE2A0A0H3JHG3 A0A0H3JHG3_ECO57+-+NT
FCcdBP62554 CCDB_ECOLI+- ~ NT
VcHigB2Q9KMA6·HIGB2_VIBCH+-+NT
barnaseP00648 RNBR_BACAM+- ~ NT
VcParE2Q9KMJ0 Q9KMJ0_VIBCH---+
Table 2. Primers used for Gibson assembly of toxins in pJYP1.
Table 2. Primers used for Gibson assembly of toxins in pJYP1.
ToxinPrimerSequence
EcMazF-HisMazFHis_F15′-ccttcttctattgtggatgctttacaatggtaagccgatacgtacccg-3′
MazFHis_R15′-tccccactcgccagatttacgaagatcagtgatgatgatgatgatggctgc-3′
His-barnaseHisbarnase_F15′-ccttcttctattgtggatgctttacaatgggcagcagccatcacc-3′
Hisbarnase_R15′-tccccactcgccagatttacgaagagatctttatctgatttttgtaaaggtctgataatggtccg-3′
barnase-HisbarnaseHis_F15′-ccttcttctattgtggatgctttacaatggcacaggttatcaacacgtttgacgg-3′
barnaseHis_R15′-tccccactcgccagatttacgaagatcagtgatgatgatgatgatggctgc-3′
His-VcHigB2HisHigB2_F15′-ccttcttctattgtggatgctttacaatgggcagcagccatcacc-3′
HisHigB2_R15′-tccccactcgccagatttacgaagatcacgattgctcattgcgc-3′
VcParE2-HisVcParE2His_F15′-ccttcttctattgtggatgctttacaatgaaaccatttaatcttaccgtcgccgc-3′
VcParE2His_R15′-tccccactcgccagatttacgaagatcagtgatgatgatgatgatgtgcg-3′
P1Doc-HisDocHis_F15′-ccttcttctattgtggatgctttacaatgaggcatatatcaccggaagaac-3′
DocHis_R15′-tccccactcgccagatttacgaagatcagtgatgatgatgatgatggctgc-3′
EcParE2-HisEcParE2His_F15′-ccttcttctattgtggatgctttacaatgttacccgtgttatggcttgaaagcgc-3′
EcParE2His_R15′-tccccactcgccagatttacgaagatcagtgatgatgatgatgatggctgc-3′
FCcdBCcdB_F1
CcdB_R1
5′-cttcttctattgtggatgctttacaatgcagtttaaggtttacacctata-3′
5′-cactcgccagatttacgaagagatcttatattccccagaacatcaggtta-3′
Table 3. Plasmids used in this study. Toxins cloned in pJYP1 are P1Doc, P1DocH66Y, EcMazF, EcMazFE24A, EcParE2, VcHigB2, barnase and FCcdB. For pJYP2: P1Doc*, P1DocH66Y, EcMazF, EcMazFE24A, EcParE2, VcHigB2, barnase* and FCcdB*. For pJYP3: P1DocH66Y, EcMazF and EcMazFE24A.
Table 3. Plasmids used in this study. Toxins cloned in pJYP1 are P1Doc, P1DocH66Y, EcMazF, EcMazFE24A, EcParE2, VcHigB2, barnase and FCcdB. For pJYP2: P1Doc*, P1DocH66Y, EcMazF, EcMazFE24A, EcParE2, VcHigB2, barnase* and FCcdB*. For pJYP3: P1DocH66Y, EcMazF and EcMazFE24A.
PlasmidsDescription
pJYP1_toxinFdeR—PfdeA—RSB12—toxin in HpaI/XhoI site of pET22b
pJYP2_toxinLacI—Ptac—RStheo—toxin in BglII/XhoI site of pET22b
pJYP3_toxinLacI—Ptac—RSB12—toxin in BglII/XhoI site of pET22b
pJYP4_VcParE2AraC—PBAD—RStheoVcParE2 in BglII/XhoI site of pET22b
Table 4. Plasmid specific (ori) and genome specific (dxs) primer sets used for qPCR.
Table 4. Plasmid specific (ori) and genome specific (dxs) primer sets used for qPCR.
Primer NamePrimer SequencePrimer LengthProduct SizeSource
ori.FWATACCTGTCCGCCTTTCTCC20 nt86 bp[42]
ori.RVGAACGACCTACACCGAACTGAG22 nt86 bp[42]
dxs.FWCGAGAAACTGGCGATCCTTA20 nt113 bp[43]
dxs.RVCTTCATCAAGCGGTTTCACA20 nt113 bp[43]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Vandierendonck, J.; Girardin, Y.; De Bruyn, P.; De Greve, H.; Loris, R. A Multi-Layer-Controlled Strategy for Cloning and Expression of Toxin Genes in Escherichia coli. Toxins 2023, 15, 508. https://doi.org/10.3390/toxins15080508

AMA Style

Vandierendonck J, Girardin Y, De Bruyn P, De Greve H, Loris R. A Multi-Layer-Controlled Strategy for Cloning and Expression of Toxin Genes in Escherichia coli. Toxins. 2023; 15(8):508. https://doi.org/10.3390/toxins15080508

Chicago/Turabian Style

Vandierendonck, Jessie, Yana Girardin, Pieter De Bruyn, Henri De Greve, and Remy Loris. 2023. "A Multi-Layer-Controlled Strategy for Cloning and Expression of Toxin Genes in Escherichia coli" Toxins 15, no. 8: 508. https://doi.org/10.3390/toxins15080508

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop